


STUDIENUPDATE HÄMATOLOGIE

AML: STUDIEN DER AMLCG


K. Spiekermann

Frankfurt, 26.03.2015




AMLCG-STUDIES 1981-2015

Patients < 60 Years




AMLCG-STUDIES 1981-2015



Patients 60+ Years





ÜBERBLICK AML: DIAGNOSTIK UND THERAPIE INTENSIV BEHANDELBARE JÜNGERE PATIENTEN





DOSE DENSITY




Double Induction – AML-CG



DOSE DENSITY



AML-CG 2004 Pilot - Overall Survival



AML-CG 2008 – S-HAM Regimen

Drug	day 1	day 2	Day 3	Day 4	day 5	day 6	day 7	day 8	day 9	day 10	day 11
AraC	■ ■	■ ■						■ ■	■ ■		
Mitoxantrone			■	■						■	■

AraC dosing, patients <60 years:

3 g/m², 3 hours continous infusion, bid days 1 – 2 and days 8 – 9

AraC dosing, patients ≥60 years:

1 g/m², 3 hours continous infusion, bid days 1 – 2 and days 8 – 9

Mitoxantrone dosing:


10 mg/m², 30 minutes infusion, days 3 – 4 and days 10 – 11



AML-CG 2008



Patient Status:

„Young“ [<60 (-70) Years]



Patient Status:

„Old“ [≥ 60 (-70) Years]



Response Rate

ORR by therapy:


	ORR		Σ N (%)
	No N (%)	Yes N (%)	
Standard	51 (28)	133 (72)	184 (48)
S-HAM	47 (23)	156 (77)	203 (52)
Σ	98 (25)	289 (75)	387 (100)

$ORR_{\text{Standard}} = 72.28$ (95%CI for $ORR_{\text{Standard}} = 65.22 - 78.61$)

$ORR_{\text{S-HAM}} = 76.85$ (95%CI for $ORR_{\text{S-HAM}} = 70.43 - 82.46$)

$ORR_{\text{(S-HAM - STANDARD)}} = 5\%$

$p = 0,202$



Results AML-CG 2008

- **S-HAM + 5% ORR – not significant**
- **OS / EFS / RFS – not significant**
- **Dose-dense therapy feasible in general AML population (- 80+)**




Lessons from AML-CG 2008

- **1g vs 3g AraC substantially less toxic**
- **no 3g AraC doses in (dose-dense) induction**
- **1g S-HAM with best ED rates in AML-CG studies**
- **> 14 days shortening of critical neutropenia**




AML CG 2014: CONCEPTS



INDUCTION THERAPY

RISK STRATIFICATION




POSTREMISSION THERAPY




AML CG 2014: INDUCTION

R




MRD CUTOFF TO PREDICT RELAPSE IN CBF/NPM1 MUTATED AML

CBF β -MYH11




CBF β -MYH11 / ABL ratio

RUNX1-RUNX1T1



RUNX1-RUNX1T1 / ABL ratio


NPM1



NPM1 / ABL ratio

Hubmann, Haemaologica 2014
Hubmann (unpublished)


MRD DURING THERAPY AND FOLLOW UP



MRD Marker ¹	Time point of stratification	Cut-off ²	Cut-off during maintenance ³
NPM1 Mutation	After induction/ prior to consolidation	0.01	0.1
CBF β - MYH11	After induction/ prior to consolidation	0.1	0.2
RUNX1-RUNX1T1	After consolidation	0.05	0.1



AML CG 2014: POSTREMISSION



Acknowledgements

- **LMU AML Working Group München**

- Prof. Hiddemann
- PD Fiegl
- Prof. Spiekermann
- Prof. Subklewe
- Dr. Unterhalt
- Dr. Baumgartner
- Dr. Pastore
- Dr. Metzeler
- Dr. Hubmann
- Dr. Lichtenegger

- **FLAMSA-Protocol**

- Klinikum Augsburg
- University of Essen
- University of Munich
- DKD Wiesbaden
- University of Münster
- University of Münster
- University of Regensburg
- PD Dr. Schmid
- Prof. Beelen
- Dr. Tischer
-
- Prof. Büchner
- Prof. Faldum/ Dr.Sauerland
- Prof. Holler

- **ETAL-1-Protocol**

- University of Dresden
- University of Münster
- University of Essen
- University of Munich
- Prof. Bornhäuser
- Prof. Stelljes
- Prof. Beelen
- Dr. Tischer, Prof. Hiddemann

- **AML Working Group Regensburg**

- Prof. Braess
- Dr. Braess

- **Lab. for Leukemia Diagnostics**

- Prof. Spiekermann
- Prof. Subklewe
- PD Fiegl
- Dr. S. Schneider
- Dr. Hubmann

- **Clinical Study Center Münster**

- Prof. Faldum/ Dr.Sauerland
- Dr. Amler, Dr. Görlich

- **AMGEN**

- Herr Martin

